CYTK
Cytokinetics, Incorporated · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cytokinetics.com
- Employees(FY) 409
- ISIN US23282W6057
Performance
-7.01%
1W
-13.72%
1M
-22.58%
3M
+87.91%
6M
-28.7%
YTD
+57.45%
1Y
Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Investment Analysis Report: CYTK
Overview
In this investment analysis report, we will delve into the financial performance and health of CYTK, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial statements over the past three years to gain insights into its valua...
Technical Analysis of CYTK 2024-05-10
Overview:
In analyzing the technical indicators for CYTK over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been declining, indicating a ...
Recent News & Updates
- 2024-05-17 07:30
- 2024-05-16 19:30
- 2024-05-15 07:30
- 2024-05-14 19:30
- 2024-05-14 16:01
Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug(Investor's Business Daily)
- 2024-05-13 17:24
Health Care Roundup: Market Talk(The Wall Street Journal)
- 2024-05-13 16:08
Cytokinetics Slumps Despite 'Pristine' Results For Bristol Myers-Rivaling Heart Drug(Investor's Business Daily)
- 2024-05-13 09:33
- 2024-05-13 09:33
- 2024-05-12 21:43
- 2024-05-12 21:33
- 2024-05-12 21:33
- 2024-05-12 21:11
- 2024-05-10 12:37
- 2024-05-10 07:47
Cytokinetics First Quarter 2024 Earnings: Misses Expectations(Simply Wall St.)
- 2024-05-09 10:48
- 2024-05-09 10:46
- 2024-05-09 07:01
- 2024-05-08 22:46
- 2024-05-08 17:18
Cytokinetics Q1 Net Loss Narrows, Revenue Declines(MT Newswires)
- 2024-05-08 17:10
- 2024-05-08 16:06
Cytokinetics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-08 16:00
Cytokinetics Reports First Quarter 2024 Financial Results(GlobeNewswire)
- 2024-05-08 09:00
- 2024-05-08 07:30
- 2024-05-08 07:30
- 2024-05-08 05:10
- 2024-05-08 04:00
Cytokinetics Reports First Quarter 2024 Financial Results(Globenewswire)
- 2024-05-08 02:23
- 2024-05-07 19:30
Page 1 of 8
previousnext